News & Updates

The association between proton pump inhibitor (PPI) use and increased cardiovascular disease risk, as seen in many observational studies, is probably caused by residual confounding related to conditions with PPI treatment instead of a true correlation, as suggested by negative findings in a self-controlled case series (SCCS) study.

New drug applications approved by US FDA as of 01 - 15 July 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Taking diltiazem and direct oral anticoagulants (DOACs) together appears to contribute to increased bleeding risk in patients with atrial fibrillation (AF), regardless of the presence of chronic kidney disease, as shown in a study.

Exposure to single or multiple drugs can have extensive disruptive effects on the human gut microbiome, a new study has found.

Second-line treatment with the CAR* T-cell therapy axicabtagene ciloleucel (axi-cel) led to significantly longer event-free survival (EFS) in patients aged ≥65 years with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) compared with standard of care (SoC), according to a preplanned subgroup analysis of the ZUMA-7** trial presented at EHA 2022.